Indeed, tadekinig alfa, a human recombinant IL-18 binding protein (IL-18BP) (Gabay et al., 2018) is being actively studied in Still Disease and other autoinflammatory diseases (NCT03113760) and GSK1070806, a humanized IgG1/kappa antibody directed against the soluble cytokine interleukin-18 (IL-18), is starting to be employed in type 2 Diabetes Mellitus (McKie et al., 2016), renal transplant recipient (Wlodek et al., 2021) and Crohn’s disease.19 However, their use in EoE patients has not yet been studied. This evidence concerns the gene IL18 and systemic-onset juvenile idiopathic arthritis.